EZH2 and Ewing sarcoma: Despite preclinical studies in hepatocellular carcinoma [279], PCa [208], head and neck cancer [280] and Ewing sarcoma [281] showing that the combination of EZH2 inhibitors and CPIs has a synergistic effect, there are no studies investigating the immunological consequences of these combinations.